The pharmaceutical industry’s continued investment in topical drug delivery has placed renewed attention on the science behind semisolid formulation development. From prescription dermatology products to complex systems and mucosal delivery applications, sponsors are increasingly looking for development partners capable of navigating the intricate balance between formulation performance, manufacturability, regulatory expectations, and patient experience.

At CPL, this balance is achieved through decades of specialized expertise in semisolid formulation development, advanced analytical capabilities, and scalable GMP manufacturing. CPL’s recently released scientific resources provide a deeper look into the complexity of cream formulation science and the critical role of advanced in vitro testing methods in modern topical drug development.

Why Semisolid Formulations Require Specialized Expertise

Creams, gels, ointments, and lotions may appear straightforward from their appearance, but their internal structures are highly sophisticated. Modern semisolid formulations involve carefully engineered interactions between oils, water phases, emulsifiers, polymers, permeation enhancers, preservatives, and active pharmaceutical ingredients to balance the qualitative (Q1), quantitative (Q2), and microstructure (Q3) framework.

As outlined in CPL’s recent scientific newsletter, even minor changes in excipient selection, droplet size, emulsification energy, or cooling profiles can significantly alter microstructure,  product stability, release kinetics, patient experience, and overall therapeutic performance.

This is especially important in today’s regulatory environment, where Quality by Design (QbD) principles increasingly guide formulation development and manufacturing expectations. Sponsors developing semisolid products must demonstrate clear control over critical quality attributes (CQAs) and critical process parameters (CPPs) throughout development and commercialization.

Understanding the Science Behind Emulsion-Based Drug Delivery

One of the most valuable aspects of CPL’s scientific overview is its detailed explanation of the different semi-solid systems used throughout the industry and how their structures directly influence product performance.

Oil-in-water (O/W) creams, for example, are often selected for products requiring a lighter texture, rapid absorption, and strong patient acceptability. Water-in-oil (W/O) systems provide enhanced occlusivity and sustained moisturization, making them suitable for formulations where prolonged skin hydration is critical. More advanced multiphase systems, such as W/O/W emulsions and emulgels, enable controlled release profiles and incorporation of both hydrophilic and lipophilic APIs. CPL has also developed platform technology enabling the use of liposomes in semisolid drug products. This new concept enables challenging molecules to cross the skin lipid barrier and reach the targeted sites across the different skin layers.

The ability to properly design, characterize, optimize, and scale these systems requires extensive expertise in formulation, skin testing, rheology, microstructural analysis, and process engineering.

The Growing Importance of IVRT and IVPT Testing in Dermatopharmacokinetic Understanding

As topical dosage forms become increasingly sophisticated, analytical testing methods such as In Vitro Release Testing (IVRT) and In Vitro Permeation Testing (IVPT) have become essential tools during formulation development for Q3 characterization.

CPL’s Skin Lab capabilities presentation highlights how these studies help sponsors evaluate drug release profiles, assess permeation through biological barriers, optimize formulations, support regulatory submissions, and ensure batch-to-batch consistency.

IVRT studies are particularly valuable for establishing release characteristics and demonstrating formulation Q3 equivalence under FDA and EMA expectations. IVPT studies provide further insight into how formulations interact with skin and mucosal tissues, helping developers better understand permeation efficiency and drug distribution within skin layers.

For sponsors developing novel semisolids (NDA, 505(b)), generic/ANDA topical products, these studies play a crucial role in both development strategy and regulatory alignment.

CPL’s Integrated Skin Lab Capabilities

CPL’s Skin Lab provides a comprehensive suite of services designed to support semisolid formulation development from early-stage screening through commercial manufacturing support.

Their capabilities include:

  • IVPT method development
  • IVRT method development and validation
  • Formulation screening
  • Drug distribution studies in skin layers
  • HPLC and UPLC method development
  • Comparative equivalence analysis
  • Advanced Franz diffusion cell testing
  • GMP-compliant analytical environments
  • LC-MS/MS quantification support

The lab operates with both manual and automated Franz diffusion systems, enabling efficient testing across multiple formulations and study conditions.

Combined with CPL’s commercial manufacturing capabilities, these analytical services create a highly integrated product development environment that allows sponsors to move seamlessly from formulation optimization into scalable production.

From Lab Scale to Commercial Manufacturing

One of CPL’s major differentiators is its ability to bridge research-scale development with large-scale GMP manufacturing.

According to CPL’s scientific newsletter, the organization supports batch sizes ranging from 20 kg to 5,000 kg while maintaining homothetic scale-up of critical process parameters to ensure reproducibility between development and commercial production.

CPL also supports complex formulation requirements involving:

  • Male and female hormonal products
  • Potent APIs
  • Oxidation-sensitive compounds
  • Flammable excipients
  • Nitrogen blanketing processes

These capabilities are supported by dedicated GMP suites and flexible packaging solutions, including aluminum tubes, laminate tubes, jars, sachets, and metered-dose pumps.

Download CPL’s Scientific Resources

For pharmaceutical companies exploring semisolid formulation development and optimization, or advanced IVRT/IVPT testing strategies, CPL’s latest scientific materials provide valuable technical insight into the evolving landscape of topical product development.

To learn more about:

  • Semi-solid formulation science
  • QbD approaches for semisolids
  • IVPT and IVRT methodologies
  • Skin permeation testing
  • Regulatory alignment for topical products
  • CPL’s integrated Skin Lab capabilities

We encourage you to download and review CPL’s latest technical resources and connect with the CPL team to discuss your upcoming formulation and analytical development needs.

Technical Resources:

  • “Understanding and Developing Cream-Based Semisolid Systems: A Scientific Overview”
  • “Introduction to Skin Lab Services”